

**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Attorney Docket No.
25142-0002001Application No.
10/797,903Applicant
Yamamoto et al.Filing Date
March 10, 2004Group Art Unit
1628**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
AP	1	5,624,937	04-1997	Reel et al.			
	2	5,658,374	08-1997	Glover			
	3	6,534,535	03-2003	Zhu et al.			
	4	6,821,987	11-2004	Kubo et al.			
	5	7,612,092	11-2009	Funahashi et al.			
	6	7,612,208	11-2009	Matsushima et al.			
	7	2004/0053908	03-2004	Funahashi et al.			
	8	2004/0242506	12-2004	Barges Causeret et al.			
	9	2004/0253205	12-2004	Yamamoto et al.			
	10	2005/0187236	08-2005	Tsuruoka et al.			
	11	2006/0004029	01-2006	Tsuruoka et al.			
	12	2006/0057195	03-2006	Nonomura et al.			
	13	2007/0004773	01-2007	Sakaguchi et al.			
	14	2007/0027318	02-2007	Kubo et al.			
	15	2007/0037849	02-2007	Naito et al.			
	16	2007/0078159	04-2007	Matsushima			
AP	17	2007/0117842	05-2007	Arimoto et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
AP	18	2 253 848	09-1992	GB				
	19	WO 00/43384	07-2000	WO				
	20	WO 00/44728	08-2000	WO				
	21	WO 00/47212	08-2000	WO				
	22	WO 00/50405	08-2000	WO				
	23	WO 00/71097	11-2000	WO				
AP	24	WO 02/16348	02-2002	WO			Abst.	

Examiner Signature

Date Considered

EXAMINER: Initials
next communication to applicant.

Draw line through citation if not in conformance and not considered. Include copy of this form with

**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Attorney Docket No.
25142-0002001Application No.
10/797,903Applicant
Yamamoto et al.Filing Date
March 10, 2004Group Art Unit
1628**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
AP	25	WO 03/13529	02-2003	WO				
	26	WO 04/35052	04-2004	WO				
	27	WO 04/64730	08-2004	WO			Abst.	
	28	WO 05/44788	05-2005	WO				
	29	WO 06/30826	03-2006	WO			Abst.	
	30	WO 06/137474	12-2006	WO			Abst.	
	31	WO 96/39145	12-1996	WO			Abst.	
	32	WO 92/20642	11-1992	WO				
	33	WO 95/15758	06-1995	WO				
	34	WO 95/19774	07-1995	WO				
	35	WO 96/09294	03-1996	WO				
	36	WO 96/26997	09-1996	WO				
	37	WO 96/40142	12-1996	WO				
	38	WO 97/03069	01-1997	WO				
	39	WO 97/13760	04-1997	WO				
	40	WO 97/13771	04-1997	WO				
	41	WO 97/21437	06-1997	WO				
	42	WO 97/38984	10-1997	WO				
	43	WO 98/00134	01-1998	WO				
	44	WO 98/02434	01-1998	WO				
	45	WO 98/02437	01-1998	WO				
	46	WO 98/02438	01-1998	WO				
	47	WO 98/13350	04-1998	WO				
	48	WO 98/23613	06-1998	WO				
	49	WO 98/32436	07-1998	WO				
	50	WO 98/50346	11-1998	WO				
	51	WO 98/52558	11-1998	WO				

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Attorney Docket No.
25142-0002001Application No.
10/797,903Applicant
Yamamoto et al.Filing Date
March 10, 2004Group Art Unit
1628**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
AP	52	WO 99/32110	07-1999	WO				
	53	WO 99/32111	07-1999	WO				
	54	WO 99/35132	07-1999	WO				
	55	WO 99/43654	09-1999	WO				
	56	0 405 425	08-1998	EP				
	57	0 602 851	10-1996	EP				
	58	0 684 820	08-2001	EP				
	59	0 795 556	09-1997	EP				
	60	0 837 063	04-1998	EP				
	61	1 029 853	02-2004	EP				
	62	1 797 881	04-2009	EP				
	63	2001-131071	05-2001	JP				
	64	2002-003365	01-2002	JP			Abst.	
	65	2003-026576	01-2003	JP			Abst.	
	66	2004-155773	06-2004	JP			Abst.	
	67	2005-501074	01-2005	JP			Abst.	
	68	1022874	01-1989	JP			Abst.	
	69	11-143429	05-1999	JP			Abst.	
	70	11-501343	02-1999	JP			Abst.	
	71	4341454	11-1992	JP			Abst.	
	72	7-176103	07-1995	JP			Abst.	
	73	8-045927	02-1996	JP			Abst.	
AP	74	63-028427	02-1988	JP			Abst.	
	75	2006-515884	06-2006	JP			Abst.	
							Abst.	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
------------------	-----------	----------

Examiner Signature

Date Considered

8/24/2010

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Attorney Docket No.
25142-0002001Application No.
10/797,903Applicant
Yamamoto et al.Filing Date
March 10, 2004Group Art Unit
1628**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
AP	91	Myers et al., "The Preparation and SAR of 4-(Anilino), 4-(Phenoxy), and 4-(Thiophenoxy)-Quinazolines: Inhibitors of p56 ^{lck} and EGF-R Tyrosine Kinase Activity," <i>Bioorg Med Chem Lett</i> , 1997, 7(4):417-420
	92	Nakamura et al., "E7080(ER-203492-00), a Novel VEGF Receptor Tyrosine Kinase Inhibitor-II. Effects on Growth of Human Tumor Xenografts and Life Span of Mice in Colon 38 Orthotopic Transplantation Model," Abstract # 52, <i>AACR</i> , Toronto, Canada, April 5-9, 2003
	93	Nugiel et al., "Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 2. Probing the Ideno Ring Substituent Pattern," <i>J Med Chem</i> , 2002, 45(24):5224-5232
	94	Taguchi et al., "A novel orally active inhibitor of VEGF receptor tyrosine kinases KRN951: Anti-angiogenic and anti-tumor activity against human solid tumors," <i>Proc Am Assoc Cancer Res</i> , 2004, 45:1070-1071, Abstract 2575
	95	Takano et al., "Thermal recording materials with improved background stability," <i>CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US</i> , 1996, XP002443195
	96	Wedge et al., "AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer," <i>Cancer Res</i> , 2005, 65(10):4389-4400
	97	Yamamoto et al., "E7080 (ER-203492-00), a Novel VEGF Receptor Tyrosine Kinase Inhibitor-III. Significant prolongation of life span in mice transplanted with human ovarian carcinoma based on inhibition of VEGF signaling," Abstract # 50, <i>AACR</i> , Toronto, Canada, April 5-9, 2003
	98	Yamamoto et al., "E7080 a Novel Multitargeted Tyrosine Kinase Inhibitor, has direct anti-tumor efficacy via inhibition of KIT signaling in small cell lung cancer," Abstract #4636, <i>AACR</i> , Orlando, FL, March 27-31, 2004
AP	99	Yamamoto et al., "E7080 an Oral Multi-Targeted Tyrosine Kinase Inhibitor Has Direct Anti-Tumor Efficacy via Inhibition of KIT Signaling in Gastrointestinal Stromal Tumor (GIST)," Abstract #4038, <i>97th Annual Meeting AACR</i> , Washington, DC, April 1-5, 2006
	100	Office Action directed at application No. 200580026488.7 issued on June 26, 2009 (NEED ENGLISH TRANSLATION)
AP	101	Examiner Elia Bonneville, Supplementary European Search Report in EP 04 81 8213 mailed 30 July 2007, 3 pages
	102	Unknown Korean Examiner, Notice Requesting Submission of Opinion in Application No. 10-2007-7013993 mailed 31 July 2007, 9 pages (English translation)
	103	Examiner D Margaret M Seaman, Non-Final Office Action in U.S. Serial No. 10/577,531 mailed 23 September 2008, 17 pages
	104	Examiner Anna Pagonakis, Non-Final Office Action in U.S. Serial No. 10/797,903 mailed 20 August 2009, 12 pages
	105	Examiner Anna Pagonakis, Non-Final Office Action in U.S. Serial No. 10/797,903 mailed 11 December 2007, 12 pages
AP	106	Authorized officer Masashi Honda, International Preliminary Report on Patentability in PCT/JP2006/312487 mailed 10 January 2008, 7 pages
	107	Unknown Japanese Examiner, Office Action in Application No. P2005-516605 mailed 1 June 2010, 3 pages

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Attorney Docket No.
25142-0002001Application No.
10/797,903Applicant
Yamamoto et al.Filing Date
March 10, 2004Group Art Unit
1628**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
JF	76	Anderson and Flora, "Preparation of Water-Soluble Compounds Through Salt Formation," <u>The Practice of Medicinal Chemistry</u> , 1996, pp. 739-754
	77	Clark et al., "Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors," <u>Clin Cancer Res</u> , 2005, 11(15):5472-5480
	78	Furitsu and Suzuki, "Stable medicinal compositions of quinolinecarboxamide derivative," CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, 2006, XP002520305
	79	Furuta et al., "Synthesis and Biological Evaluation of Selective Inhibitors of PDGF Receptor Auto Phosphorylation," 226 th ACS National Meeting, September 7-11, 2003, New York, NY, Abstract No. 64
	80	Gardner et al., "In Vitro Activity of Sorghum-Selective Fluorophenyl Urea Herbicides," <u>Pesticide Biochem Physiol</u> , 1985, 24(3):285-297
	81	Haleblian, "Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications," <u>J Pharm Sci</u> , 1975, 64(8):1269-1288
	82	Hayek et al., "An In Vivo Model for Study of the Angiogenic Effects of Basic Fibroblast Growth Factor," <u>Biochem Biophys Res Commun</u> , 1987, 147(2):876-880
	83	Jakeman et al., "Developmental Expression of Binding Sites and Messenger Ribonucleic Acid for Vascular Endothelial Growth Factor Suggests a Role for This Protein in Vasculogenesis and Angiogenesis," <u>Endocrinology</u> , 1993, 133(2):848-859
	84	Matsui et al., "E7080(ER-203492-00), a Novel VEGF Receptor Tyrosine Kinase Inhibitor-I. Characterization as an Angiogenesis Inhibitor," Abstract # 51, <u>AACR</u> , Toronto, Canada, April 5-9, 2003
	85	Matsui et al., "E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition," <u>Int J Cancer</u> , 2008, 122:664-671
	86	Matsui et al., "E7080, a Novel Multi-Receptor Tyrosine Kinases Inhibitor, Inhibited <i>in vitro</i> / <i>in vivo</i> VEGF- and SCF-driven Angiogenesis in SCLC Cell Line," Abstract #146, <u>EORTC-NCI-AACR</u> , Geneva, Switzerland, September 28-October 1, 2004
	87	Matsui et al., "Quantitative Analysis of the Profile of Tumor Vessels may be Useful as Predictive Biomarkers for E7080, a KDR Tyrosine Kinase Inhibitor," Abstract #4631, <u>98th AACR Annual Meeting</u> , Los Angeles, CA, April 14-18, 2007
	88	Matsui et al., "VEGFRs inhibitor E7080 inhibits lymph node metastasis of human breast carcinoma, by preventing murine lymphatic endothelial cells from lymphangiogenesis," Abstract # PD12-8, <u>18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics</u> , Prague, Czech Republic, November 7-10, 2006
	89	Mendel et al., "In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship," <u>Clin Cancer Res</u> , 2003, 9:327-337
JF	90	Miyazaki et al., "Synthesis, Structure and Biological Activity Relationship of E7080 and its Derivatives as Novel and Potent Antiangiogenic Protein Tyrosine Kinase Inhibitors Including the VEGF Receptors, FGFR1 Receptor and PDGF Receptor," Abstract B-15, <u>AIMECS03</u> , Kyoto, Japan, October 14-17, 2003

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.